Please use this identifier to cite or link to this item:
Title: The use of Buproprion for smoking cessation in rural NSW
Contributor(s): Wong, Bo S (author); Fraser, John  (author)
Publication Date: 2004
DOI: 10.1111/j.1038-5282.2004.00554.x
Handle Link:
Abstract: Smoking is a major cause of Australian deaths. After a quit attempt, 5-10% of smokers maintain abstinence. Brief advice or nicotine-replacement therapy behavioural support can increase success by a further 2-8%. Bupropion assists smoking cessation. Its use with behavioural therapy improves abstinence by 10-14% compared to placebo. We aimed to estimate the point-prevalence rate of abstinence for rural patients prescribed bupropion. Behavioural support is limited in rural areas. In 2001, slow-released bupropion (Zyban SR: Glaxo Smith Kline; Boronia, Victoria) was added to the Pharmaceutical Benefits Scheme coinciding with more smokers requesting therapy.
Publication Type: Journal Article
Source of Publication: Australian Journal of Rural Health, 12(1), p. 38-39
Publisher: Wiley Interscience for the National Rural Health Alliance
Place of Publication: Bognor Regis, UK
ISSN: 1440-1584
Field of Research (FOR): 111502 Clinical Pharmacology and Therapeutics
111708 Health and Community Services
Peer Reviewed: Yes
HERDC Category Description: C1 Refereed Article in a Scholarly Journal
Statistics to Oct 2018: Visitors: 109
Views: 112
Downloads: 0
Appears in Collections:Journal Article

Files in This Item:
2 files
File Description SizeFormat 
Show full item record


checked on Nov 30, 2018

Page view(s)

checked on Dec 29, 2018
Google Media

Google ScholarTM



Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.